IRNEUTRAL

Return on Equity (ROE)

5.7%

Updated 128h ago

Sector Performance

22th percentile

IR

5.7%

Sector Median

13.8%

Sector Avg

31.4%

📊

Deep Analysis

Return on Equity (ROE) measures how much profit a company generates for each dollar of shareholder equity.

IR’s current ROE of 5.7% is well below the sector median of 13.8%, placing it in the 22nd percentile among peers. No year-over-year or quarter-over-quarter changes are available, and the trend direction over the last eight quarters is also not provided. Without any trend data, it is impossible to determine whether this low ROE is improving or worsening. The combination of a low absolute ROE and the absence of trend introduces additional uncertainty about the company’s profitability trajectory. This metric supports the overall NEUTRAL verdict because the weak relative performance is not accompanied by any indication of deterioration, yet it offers no sign of improvement either.

Frequently Asked Questions

What does the Return on Equity (ROE) tell investors about IR?

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.

How is the Return on Equity (ROE) calculated?

Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.

Who are IR's closest peers by Return on Equity (ROE)?

The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).

The Formula

Net Income / Shareholders' Equity

Why It Matters

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.

Advertisement

Master IR's Valuation

Get the complete institutional research report covering all fundamental and technical metrics.

View full IR research report

Free account — no credit card

IR

5.7%

Sector Median

13.8%

Sector Avg

31.4%

How IR's Return on Equity (ROE) compares to sector peers.

Not financial advice. Research tool only. Data may be delayed.